BUCHI, FRANCESCA
BUCHI, FRANCESCA
Medicina Sperimentale e Clinica
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes
2014 Alhan, Canan; Westers, Theresia M.; van der Helm, Lieke H.; Eeltink, Corien; Huls, Gerwin; Witte, Birgit I.; Buchi, Francesca; Santini, Valeria; Ossenkoppele, Gert J.; van de Loosdrecht, Arjan A.
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.
2011 Buchi F; Pastorelli R; Ferrari G; Spinelli E; Gozzini A; Sassolini F; Bosi A; Tombaccini D; Santini V
Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance.
2007 Ferrari G; Pastorelli R; Buchi F; Spinelli E; Gozzini A; Bosi A; Santini V.
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
2012 Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V.
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
2012 Spinelli E;Caporale R;Buchi F;Masala E;Gozzini A;Sanna A;Sassolini F;Valencia A;Bosi A;Santini V
Effetto dei farmaci ipometilanti, azacitidina e decitabina, sul proteoma e sul rimodellamento cromatinico di cellule di Leucemia Mieloide Acuta AML1/ETO positive
2013 FRANCESCA BUCHI
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
2014 VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.
2014 Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V.
Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.
2012 E. Masala; A. Valencia; F. Buchi; D. Nosi; E. Spinelli; A. Gozzini; F. Sassolini; A. Sanna; S. Zecchi; A. Bosi; V. Santini
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.
2012 Buchi, Francesca; Spinelli, E; Masala, E; Gozzini, A; Sanna, A; Bosi, Alberto; Ferrari, G; Santini, Valeria
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.
2012 Buchi F; Spinelli E; Masala E; Gozzini A; Sanna A; Bosi A; Ferrari G; Santini V.
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
2014 Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V.
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
2015 Meldi, Kristen; Qin, Tingting; Buchi, Francesca; Droin, Nathalie; Sotzen, Jason; Micol, Jean-Baptiste; Selimoglu-Buet, Dorothée; Masala, Erico; Allione, Bernardino; Gioia, Daniela; Poloni, Antonella; Lunghi, Monia; Solary, Eric; Abdel-Wahab, Omar; Santini, Valeria; Figueroa, Maria E.